Immunotherapy 3.0: Breakthroughs Steering the Next Generation of Cancer Control.

backgroundHematologic disorders, including sickle cell disease, anemias, hemoglobinopathies, leukemias, lymphomas, and bleeding disorders, constitute a substantial and growing burden of morbidity and mortality across Africa. Structural health system constraints-limited diagnostic capacity, shortages of trained hematology specialists, fragmented blood transfusion services, and inequitable access to essential medicines-continue to drive delayed diagnosis, suboptimal treatment, and poor outcomes. Despite these challenges, recent years have witnessed important advances in laboratory strengthening, point-of-care diagnostics, access to targeted therapies, and innovative service delivery models. This narrative review synthesizes current evidence on diagnostic and therapeutic gaps in hematology care in Africa and examines emerging strategies aimed at strengthening equitable, sustainable, and context-appropriate care. RECENT

findingsRecent initiatives demonstrate measurable progress in several domains. Expansion of point-of-care testing and regional laboratory networks has improved early diagnosis of sickle cell disease and hematologic malignancies in countries such as Kenya, Uganda, and Rwanda. Access to essential therapies, including hydroxyurea for sickle cell disease and tyrosine kinase inhibitors for chronic myeloid leukemia, has improved through national insurance schemes and international partnerships in settings such as Ghana and Nigeria, although coverage remains uneven. Innovations in blood transfusion services, including drone-assisted delivery in Rwanda and strengthened voluntary donation programs in Kenya and Nigeria, have reduced delays in emergency transfusion for severe anemia. Capacity-building initiatives supported by international collaborations and professional societies have expanded continuing medical education, teleconsultation, and subspecialty training; however, workforce shortages, supply chain vulnerabilities, and financial barriers persist.

conclusionTransforming hematology care in Africa requires coordinated, system-level strategies that integrate diagnostic strengthening, equitable access to essential therapies, resilient blood transfusion services, workforce development, and digital health innovations. While country-level experiences demonstrate that targeted investments and international collaborations can yield tangible improvements, sustainable progress will depend on stronger health system financing, regional manufacturing and procurement mechanisms, regulatory support, and context-sensitive implementation research. A deliberate shift from fragmented, disease-specific interventions toward integrated, patient-centered hematology care frameworks is essential to reduce preventable morbidity and mortality and to advance equitable cancer and blood disorder outcomes across the continent.